<DOC>
	<DOC>NCT01642472</DOC>
	<brief_summary>This is a phase III, multicentre, long-term open-label extension of the phase III study: Pearl IIIextension (PGL09-027). During Pearl III (PGL09-026) and subsequent Pearl III extension (PGL09-027), patients have been exposed to a total of 4 cycles of daily 3month open-label treatment with ulipristal acetate 10mg before entering the proposed study Pearl extension 2 (PGL11-024). This proposed study consists of 4 further consecutive courses of 3 months (84 days) open label ulipristal acetate 10mg once daily treatment each separated by a drug free period.</brief_summary>
	<brief_title>PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Subject completed visit F Followup of Pearl III extension study (PGL09027) without significant deviations. Females of childbearing potential are advised to practice a nonhormonal method of contraception. Subject has a history of uterus surgery (e.g. hysterectomy, myomectomy) or uterine artery embolization in Pearl III extension (PGL09027) or afterwards that would interfere with the study assessments. Subject has taken or is likely to require treatment during the study with drugs that are not permitted by the study protocol. Subject is lactating, has a positive pregnancy test at study start or is planning a pregnancy during the course of the study. Subject has abnormal baseline findings, any other medical condition(s) or laboratory finding that, in the opinion of the investigator, might jeopardise the subject's safety or interfere with study evaluations.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>